期刊论文MACROPA highly stable chelator of Radium-223 and functionalization attempts for targeted treatment of cancer复制

DOI:复制

文献链接:复制

其他信息:

D Abou, N Thiele, A Villmer, N Gustche, F Escorcia…
2020
jnm.snmjournals.org
587 Objectives: Radium-223 dichloride was approved as the first alpha particle emitting radionuclide therapy in 2013. It demonstrated treatment efficiency in castrate resistant prostate cancer. Yet, 223 RaCl 2 does not accumulate directly in cancerous tissues but rather to sites associated with elevated bone turnover, which is not sufficient to trigger an effective therapeutic response for the complete eradication of bone metastases (1). To specifically target cancerous cells, it is essential to re-engineer Radium-223 alpha therapy …